國立虎尾科技大學 |

Cell Therapy = cGMP Facilities and Manufacturing /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Cell Therapy/ edited by Adrian P. Gee.
其他題名:	cGMP Facilities and Manufacturing /
其他作者:	Gee, Adrian P.
面頁冊數:	X, 692 p. 107 illus., 75 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Facility Management. -
電子資源:	https://doi.org/10.1007/978-3-030-75537-9
ISBN:	9783030755379

Cell Therapy = cGMP Facilities and Manufacturing /
Cell TherapycGMP Facilities and Manufacturing /[electronic resource] :edited by Adrian P. Gee. - 2nd ed. 2022. - X, 692 p. 107 illus., 75 illus. in color.online resource.

Part 1. Regulatory.-1. Regulation of Cell Therapy in the United States.-2. Regulatory Landscape and Emerging Trends In Advanced Therapies Manufacturing: An EU Perspective.-3. Australian Cellular Therapy Regulations -- 4. Landscape for Regenerative Medicine Manufacturing in Japan -- 5. GLP Regulations for Non-clinical studies -- 6. Ethical Considerations in Cell Therapy -- 7. Investigational New Drug Applications for Cell Therapy Products -- 8. FDA Inspections -- 9. Commercialization of Investigational Cell Therapy Products -- Part 2 Quality Systems -- 10. The Meaning of Quality -- 11. Development and Maintenance of a Quality Program -- 12. Quality Control of Cellular Therapy Products and Viral Vectors -- 13. Quality Management Software – Q-Pulse -- 14. Selection of Contract Manufacturing and Testing Organizations -- Part 3 Facility Design -- 15. Introduction: Facility Design -- 16. PACT CPFs - Examples Describing Different Cell Processing Facility Designs -- 17. Design and Operation of a Multiuse GMP Facility at the City of Hope -- 18. Design and Operation of a Multiuse GMP Facility at the University of Miami -- 19. Design of a New Academic GMP Facility for Today and Beyond at the Dana-Farber Cancer Institute -- 20. Design and Licensure of an American Cord Blood Bank -- 21. Indiana University Vector Production Facility (IUVPF) -- 22. Qualification and Commissioning of a New GMP Facility -- Part 4 Facility Infrastructure -- 23. Environmental Monitoring -- 24. GMP Facility Cleaning and Maintenance -- 25. GMP Documentation -- 26. Process Validation -- 27. Equipment Qualification -- 28. Vendor Qualification and Supply Management -- 29. Staffing, Training and Competency -- Part 5 Product Management -- 30. Product Accessioning, Tracing and Tracking -- 31. ISBT 128 in Labeling of Cellular Therapy Products -- 32. Product Processing, Manufacturing and Administration -- 33. Transport and Shipment of Cellular and Gene Therapy Products -- 34. Regenerative Medicine: The Newest Cellular Therapy -- 35. Cellular Therapy Applications for COVID-19 -- Part 6 Professional Standards and Support Organizations -- 36. Professional Standards for Cellular Therapy: The Foundation for the Accreditation of Cellular Therapy (FACT) -- 37. AABB Cell Therapy Standards -- 38. USP Standards for Cell-based Therapies -- 39. The Role of the National Institute of Standards Measurement Assurance for Cell Therapies -- 40. National Science Foundation Engineering Research Center for Cell Manufacturing Technologies (CMaT) -- 41. Financial Considerations for Academic GMP Facilities -- 42. Governmental Support Opportunities for Cellular & Gene Therapies in the United States.

This new edition presents a fully-updated and expanded look at current Good Manufacturing Practice (cGMP) for cell therapy products. It provides a complete discussion of facility design and operation including details specific to cord blood banking, cell processing, vector production and qualification of a new facility. Several chapters cover facility infrastructure including cleaning and maintenance, vendor qualification, writing a Standard Operating Procedure, staff training, and process validation. The detailed and invaluable product information covers topics like labelling, release and administration, transportation and shipment, et al. Further chapters cover relevant topics like writing and maintaining investigational new drug applications, support opportunities in North America and the European Union, commercial cell processing and quality testing services, and financial considerations for academic GMP facilities. A chapter on future directions rounds out Cell Therapy: cGMP Facilities and Manufacturing making it essential reading for any cell therapy professional involved in the development, use, or management of this type of facility. .

ISBN: 9783030755379

Standard No.: 10.1007/978-3-030-75537-9doiSubjects--Topical Terms:

671037
Facility Management.

LC Class. No.: QH573-671

Dewey Class. No.: 571.6

Cell Therapy = cGMP Facilities and Manufacturing /
LDR:05185nam a22003855i 4500 001 1090580
003 DE-He213
005 20220114091143.0
007 cr nn 008mamaa
008 221228s2022 sz | s |||| 0|eng d
020 $a 9783030755379 $9 978-3-030-75537-9
024 7 $a 10.1007/978-3-030-75537-9 $2 doi
035 $a 978-3-030-75537-9
050 4 $a QH573-671
072 7 $a PSF $2 bicssc
072 7 $a SCI049000 $2 bisacsh
072 7 $a PSF $2 thema
082 0 4 $a 571.6 $2 23
245 1 0 $a Cell Therapy $h [electronic resource] : $b cGMP Facilities and Manufacturing / $c edited by Adrian P. Gee.
250 $a 2nd ed. 2022.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a X, 692 p. 107 illus., 75 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Part 1. Regulatory.-1. Regulation of Cell Therapy in the United States.-2. Regulatory Landscape and Emerging Trends In Advanced Therapies Manufacturing: An EU Perspective.-3. Australian Cellular Therapy Regulations -- 4. Landscape for Regenerative Medicine Manufacturing in Japan -- 5. GLP Regulations for Non-clinical studies -- 6. Ethical Considerations in Cell Therapy -- 7. Investigational New Drug Applications for Cell Therapy Products -- 8. FDA Inspections -- 9. Commercialization of Investigational Cell Therapy Products -- Part 2 Quality Systems -- 10. The Meaning of Quality -- 11. Development and Maintenance of a Quality Program -- 12. Quality Control of Cellular Therapy Products and Viral Vectors -- 13. Quality Management Software – Q-Pulse -- 14. Selection of Contract Manufacturing and Testing Organizations -- Part 3 Facility Design -- 15. Introduction: Facility Design -- 16. PACT CPFs - Examples Describing Different Cell Processing Facility Designs -- 17. Design and Operation of a Multiuse GMP Facility at the City of Hope -- 18. Design and Operation of a Multiuse GMP Facility at the University of Miami -- 19. Design of a New Academic GMP Facility for Today and Beyond at the Dana-Farber Cancer Institute -- 20. Design and Licensure of an American Cord Blood Bank -- 21. Indiana University Vector Production Facility (IUVPF) -- 22. Qualification and Commissioning of a New GMP Facility -- Part 4 Facility Infrastructure -- 23. Environmental Monitoring -- 24. GMP Facility Cleaning and Maintenance -- 25. GMP Documentation -- 26. Process Validation -- 27. Equipment Qualification -- 28. Vendor Qualification and Supply Management -- 29. Staffing, Training and Competency -- Part 5 Product Management -- 30. Product Accessioning, Tracing and Tracking -- 31. ISBT 128 in Labeling of Cellular Therapy Products -- 32. Product Processing, Manufacturing and Administration -- 33. Transport and Shipment of Cellular and Gene Therapy Products -- 34. Regenerative Medicine: The Newest Cellular Therapy -- 35. Cellular Therapy Applications for COVID-19 -- Part 6 Professional Standards and Support Organizations -- 36. Professional Standards for Cellular Therapy: The Foundation for the Accreditation of Cellular Therapy (FACT) -- 37. AABB Cell Therapy Standards -- 38. USP Standards for Cell-based Therapies -- 39. The Role of the National Institute of Standards Measurement Assurance for Cell Therapies -- 40. National Science Foundation Engineering Research Center for Cell Manufacturing Technologies (CMaT) -- 41. Financial Considerations for Academic GMP Facilities -- 42. Governmental Support Opportunities for Cellular & Gene Therapies in the United States.
520 $a This new edition presents a fully-updated and expanded look at current Good Manufacturing Practice (cGMP) for cell therapy products. It provides a complete discussion of facility design and operation including details specific to cord blood banking, cell processing, vector production and qualification of a new facility. Several chapters cover facility infrastructure including cleaning and maintenance, vendor qualification, writing a Standard Operating Procedure, staff training, and process validation. The detailed and invaluable product information covers topics like labelling, release and administration, transportation and shipment, et al. Further chapters cover relevant topics like writing and maintaining investigational new drug applications, support opportunities in North America and the European Union, commercial cell processing and quality testing services, and financial considerations for academic GMP facilities. A chapter on future directions rounds out Cell Therapy: cGMP Facilities and Manufacturing making it essential reading for any cell therapy professional involved in the development, use, or management of this type of facility. .
650 2 4 $a Facility Management. $3 671037
650 2 4 $a Drug Safety and Pharmacovigilance. $3 1064651
650 1 4 $a Cell Biology. $3 593889
650 0 $a Facility management. $3 569392
650 0 $a Pharmacovigilance. $3 1163244
650 0 $a Cytology. $3 599554
700 1 $a Gee, Adrian P. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1398016
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030755355
776 0 8 $i Printed edition: $z 9783030755362
856 4 0 $u https://doi.org/10.1007/978-3-030-75537-9
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)